Skip to main content
SpringerLink
Log in

Fluticasone Propionate/Salmeterol MDPI (AirDuo RespiClick®): A Review in Asthma

  • Adis Drug Evaluation
  • Published:
Clinical Drug Investigation Aims and scope Submit manuscript

Abstract

The novel, easy-to-use, breath-actuated fluticasone propionate/salmeterol multidose dry powder inhaler (MDPI) (AirDuo RespiClick®) was recently approved in the USA for twice-daily treatment of asthma in patients aged ≥ 12 years. This inhaled corticosteroid (ICS) and long-acting β2-adrenoreceptor agonist (LABA) combination treatment is available in low-, mid- and high-dosage formulations (55/14, 113/14 and 232/14 μg, respectively). In 12-week, phase III trials in patients aged ≥ 12 years with persistent asthma, all three dosages of fluticasone propionate/salmeterol MDPI treatment produced significant improvements in lung function and other asthma symptoms compared with fluticasone propionate MDPI monotherapy or placebo MDPI. In a 26-week, phase III trial in this patient population, mid- and high-dosage fluticasone propionate/salmeterol MDPI were noninferior to mid- (250/50 μg) and high- (500/50 μg) dosage fluticasone propionate/salmeterol DPI (Advair Diskus®), respectively, in terms of improvements in lung function. Treatment-emergent adverse events (TEAEs) with fluticasone propionate/salmeterol MDPI were mostly of mild to moderate severity, with no severe TEAEs deemed to be treatment related. Although long-term pharmacovigilance is required to fully establish its safety, given the ease of use and favorable characteristics of the device and its clinical efficacy at relatively low metered doses of the active moieties, fluticasone propionate/salmeterol MDPI is an important emerging treatment option in patients aged ≥ 12 years with asthma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Global Initiative for Athma. Global strategy for asthma management and prevention (2017 update). 2017. www.ginasthma.org. Accessed 22 Feb 2018.

  2. Papi A, Haughney J, Virchow JC, et al. Inhaler devices for asthma: a call for action in a neglected field. Eur Respir J. 2011;37(5):982–5.

    Article  CAS  PubMed  Google Scholar 

  3. Virchow JC, Crompton GK, Dal Negro R, et al. Importance of inhaler devices in the management of airway disease. Respir Med. 2008;102(1):10–9.

    Article  CAS  PubMed  Google Scholar 

  4. de Boer AH, Hagedoorn P, Hoppentocht M, et al. Dry powder inhalation: past, present and future. Expert Opin Drug Deliv. 2017;14(4):499–512.

    Article  PubMed  Google Scholar 

  5. Lewis A, Torvinen S, Dekhuijzen PNR, et al. Budesonide + formoterol delivered via Spiromax® for the management of asthma and COPD: the potential impact on unscheduled healthcare costs of improving inhalation technique compared with Turbuhaler®. Respir Med. 2017;129:179–88.

    Article  CAS  PubMed  Google Scholar 

  6. Mahler DA. Peak inspiratory flow rate as a criterion for dry powder inhaler use in chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2017;14(7):1103–7.

    PubMed  Google Scholar 

  7. Pleasants RA. Dry powder inhalers and humidity: another factor to consider to ensure adequate lung delivery. Ann Am Thorac Soc. 2017;14(10):1602.

    Article  PubMed  Google Scholar 

  8. Haughney J, Price D, Barnes NC, et al. Choosing inhaler devices for people with asthma: current knowledge and outstanding research needs. Respir Med. 2010;104(9):1237–45.

    Article  PubMed  Google Scholar 

  9. Dekhuijzen PNR, Batsiou M, Bjermer L, et al. Incidence of oral thrush in patients with COPD prescribed inhaled corticosteroids: effect of drug, dose, and device. Respir Med. 2016;120:54–63.

    Article  PubMed  Google Scholar 

  10. Jones R, Martin J, Thomas V, et al. The comparative effectiveness of initiating fluticasone/salmeterol combination therapy via pMDI versus DPI in reducing exacerbations and treatment escalation in COPD: a UK database study. Int J Chron Obstruct Pulmon Dis. 2017;12:2445–54.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Price D, Roche N, Christian Virchow J, et al. Device type and real-world effectiveness of asthma combination therapy: an observational study. Respir Med. 2011;105(10):1457–66.

    Article  PubMed  Google Scholar 

  12. Teva Respiratory LLC. AirDuo™ RespiClick®: US prescribing information. 2017. https://www.accessdata.fda.gov/. Accessed 22 Feb 2018.

  13. US Center for Drug Evaluation and Research. Summary review (AirDuo RespiClick). 2017. https://www.accessdata.fda.gov/. Accessed 22 Feb 2018.

  14. Raphael G, Yiu G, Sakov A, et al. Randomized, double-blind trial evaluating the efficacy and safety of fluticasone propionate and fluticasone propionate/salmeterol delivered via multidose dry powder inhalers in patients with persistent asthma aged 12 years and older. J Asthma. 2017. https://doi.org/10.1080/02770903.2017.1350971.

    PubMed  Google Scholar 

  15. Sher L, Yiu G, Sakov A, et al. Fluticasone propionate and fluticasone propionate/salmeterol multidose dry powder inhalers compared with placebo for persistent asthma. Allergy Asthma Proc. 2017;38:1–11.

    Article  Google Scholar 

  16. Mansfield L, Yiu G, Sakov A, et al. A 6-month safety and efficacy study of fluticasone propionate and fluticasone propionate/salmeterol multidose dry powder inhalers in persistent asthma. Allergy Asthma Proc. 2017;38(4):264–76.

    Article  PubMed  Google Scholar 

  17. Data on file, Teva Respiratory LLC, 2017.

  18. Canonica GW, Arp J, Keegstra JR, et al. Spiromax, a new dry powder inhaler: dose consistency under simulated real-world conditions. J Aerosol Med Pulm Drug Deliv. 2015;28(5):309–19.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Janson C, Loof T, Telg G, et al. Difference in resistance to humidity between commonly used dry powder inhalers: an in vitro study. NPJ Prim Care Respir Med. 2016;26:16053.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Borgstrom L, Asking L, Lipniunas P. An in vivo and in vitro comparison of two powder inhalers following storage at hot/humid conditions. J Aerosol Med. 2005;18(3):304–10.

    Article  PubMed  Google Scholar 

  21. GlaxoSmithKline. Advair Diskus®: prescribing information. 2017. https://www.accessdata.fda.gov/. Accessed 22 Feb 2018.

  22. Nugent C, Yiu G, Song S, et al. The pharmacokinetics, safety, and tolerability of single, high-strength doses of fluticasone propionate and fluticasone propionate/salmeterol delivered via a novel multidose dry powder inhaler in adolescents and adults with persistent asthma. J Asthma. 2017. https://doi.org/10.1080/02770903.2017.1373392.

    PubMed  Google Scholar 

  23. Lipworth BJ. Pharmacokinetics of inhaled drugs. Br J Clin Pharmacol. 1996;42(6):697–705.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Kerwin EM, Gillespie M, Song S, et al. Randomized, dose-ranging study of a fluticasone propionate multidose dry powder inhaler in adolescents and adults with uncontrolled asthma not previously treated with inhaled corticosteroids. J Asthma. 2017;54(1):89–98.

    Article  CAS  PubMed  Google Scholar 

  25. Bernstein DI, Gillespie M, Song S, et al. Safety, efficacy, and dose response of fluticasone propionate delivered via the novel MDPI in patients with severe asthma: A randomized, controlled, dose-ranging study. J Asthma. 2017;54(6):559–69.

    Article  CAS  PubMed  Google Scholar 

  26. Miller DS, Yiu G, Hellriegel ET, et al. Dose-ranging study of salmeterol using a novel fluticasone propionate/salmeterol multidose dry powder inhaler in patients with persistent asthma. Allergy Asthma Proc. 2016;37(4):291–301.

    Article  CAS  PubMed  Google Scholar 

  27. Wlodarczyk JH, Gibson PG, Caeser M. Impact of inhaled corticosteroids on cortisol suppression in adults with asthma: a quantitative review. Ann Allergy Asthma Immunol. 2008;100(1):23–30.

    Article  CAS  PubMed  Google Scholar 

  28. Sim D, Griffiths A, Armstrong D, et al. Adrenal suppression from high-dose inhaled fluticasone propionate in children with asthma. Eur Respir J. 2003;21(4):633–6.

    Article  CAS  PubMed  Google Scholar 

  29. Greenfield JR, Samaras K. Suppression of HPA axis in adults taking inhaled corticosteroids. Thorax. 2006;61(3):272–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Mollmann H, Wagner M, Meibohm B, et al. Pharmacokinetic and pharmacodynamic evaluation of fluticasone propionate after inhaled administration. Eur J Clin Pharmacol. 1998;53(6):459–67.

    Article  CAS  PubMed  Google Scholar 

  31. US Food & Drug Administration. Long-acting beta agonists (LABAs) and inhaled corticosteroids (ICS): Drug Safety Communication—boxed warning about asthma-related death removed. 2017. https://www.fda.gov/. Accessed 22 Feb 2018.

  32. Stempel DA, Szefler SJ, Pedersen S, et al. Safety of adding salmeterol to fluticasone propionate in children with asthma. N Engl J Med. 2016;375(9):840–9.

    Article  CAS  PubMed  Google Scholar 

  33. Melani AS, Bonavia M, Cilenti V, et al. Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir Med. 2011;105(6):930–8.

    Article  PubMed  Google Scholar 

  34. Ibrahim M, Verma R, Garcia-Contreras L. Inhalation drug delivery devices: technology update. Med Devices (Auckl). 2015;8:131–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  35. Given J, Taveras H, Iverson H. Prospective, open-label evaluation of a new albuterol multidose dry powder inhaler with integrated dose counter. Allergy Asthma Proc. 2016;37(3):199–206.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

During the peer review process, the manufacturer of fluticasone propionate/salmeterol MDPI was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Author information

Authors and Affiliations

  1. Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand

    Julia Paik & Lesley J. Scott

  2. Duke Clinical Research Institute and Durham Veterans Administration Medical Center, Durham, NC, USA

    Roy A. Pleasants

Authors
  1. Julia Paik
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lesley J. Scott
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Roy A. Pleasants
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Julia Paik.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Conflicts of interest

Roy Pleasants is a speaker for AstraZeneca and has received grants and/or consulting fees or honoraria from GlaxoSmithKline and Boehringer Ingelheim. Julia Paik and Lesley Scott are salaried employees of Adis/Springer and declare no relevant conflicts of interest.

Additional information

The manuscript was reviewed by: L. Mansfield, Western Sky Medical Research, El Paso, TX, USA; L.D. Sher, Research Department, Peninsula Research Associates, Rolling Hills Estates, CA, USA.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Paik, J., Scott, L.J. & Pleasants, R.A. Fluticasone Propionate/Salmeterol MDPI (AirDuo RespiClick®): A Review in Asthma. Clin Drug Investig 38, 463–473 (2018). https://doi.org/10.1007/s40261-018-0644-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40261-018-0644-2

Search

Navigation